EUVIMEDEUVIMED entdecken
Editorial

Is marstacimab the next step in personalized and effective haemophilia management?

Johnny Mahlangu iD

Expert Review of Clinical Pharmacology · 04.03.2026 · 19 (3) · 211-213

DOI: 10.1080/17512433.2026.2636119 ↗

Kurz gefasst

Editorial in der Zeitschrift Expert Review of Clinical Pharmacology, online erschienen am 09.03.2026. Verfasst von Johnny Mahlangu. Beteiligte Einrichtung: Department of Molecular Medicine and Haematology, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

Marstacimabbleeding disordershemophilia Ahemophilia Bnon-factor therapypersonalized medicineprophylaxistissue factor pathway inhibitor

Autor:innen und Institutionen

  • Department of Molecular Medicine and Haematology, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.

ORCID-Profile: Johnny Mahlangu

Zitieren

APA

Mahlangu, J. (2026). Is marstacimab the next step in personalized and effective haemophilia management?. Expert Review of Clinical Pharmacology, 19(3), 211-213. https://doi.org/10.1080/17512433.2026.2636119

Vancouver

Mahlangu J. Is marstacimab the next step in personalized and effective haemophilia management?. Expert Review of Clinical Pharmacology. 2026;19(3):211-213. doi:10.1080/17512433.2026.2636119

BibTeX
@article{Mahlangu2026,
  author = {Mahlangu, Johnny},
  title = {Is marstacimab the next step in personalized and effective haemophilia management?},
  journal = {Expert Review of Clinical Pharmacology},
  year = {2026},
  volume = {19},
  number = {3},
  pages = {211--213},
  doi = {10.1080/17512433.2026.2636119}
}
Kostenlos starten →